0000873303 2026-06-04 2026-06-04 0000873303 1 2026-06-04 2026-06-04 0000873303 2 2026-06-04 2026-06-04 iso4217:USD pure shares S-8 S-8 EX-FILING FEES 0000873303 Sarepta Therapeutics, Inc. N/A false false S-8 Sarepta Therapeutics, Inc. Equity Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan-Common Stock, par value $0.0001 per share true 6286841 16.31 102538377.71 0.0001381 14160.55 Equity Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan-Common Stock, par value $0.0001 per share true 1500000 16.31 24465000.00 0.0001381 3378.62 127003377.71 17539.17 0.00 17539.17 (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement on Form S-8 (the "Registration Statement") shall also cover shares of the Registrant's common stock that become issuable under the Plans to prevent dilution as a result of any stock dividend, stock split, recapitalization or similar transaction. (2) Represents 6,286,841 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. 2026 Equity Incentive Plan. (3) Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, the "proposed maximum offering price per share" is calculated based on the average of the high and low prices for the Registrant's common stock as reported on the Nasdaq Global Select Market on June 3, 2026. (1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, this Registration Statement on Form S-8 (the "Registration Statement") shall also cover shares of the Registrant's common stock that become issuable under the Plans to prevent dilution as a result of any stock dividend, stock split, recapitalization or similar transaction. (3) Estimated solely for the purpose of determining the registration fee pursuant to Rule 457(c) and 457(h) under the Securities Act, the "proposed maximum offering price per share" is calculated based on the average of the high and low prices for the Registrant's common stock as reported on the Nasdaq Global Select Market on June 3, 2026. (4) Represents 1,500,000 shares of common stock reserved for future issuance under the Sarepta Therapeutics, Inc. 2026 Employee Stock Purchase Plan.